Drug Type Small molecule drug |
Synonyms DC-806, LY4100504, S 011806 + [1] |
Target |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H48FN7O4 |
InChIKeyWEXJUHWVWXUMKQ-GVIAMBBFSA-N |
CAS Registry2467732-66-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psoriasis | Phase 2 | United States | 11 May 2023 | |
Plaque psoriasis | Phase 2 | United States | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Canada | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Czechia | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Germany | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Hungary | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Poland | 02 May 2023 | |
Plaque psoriasis | Phase 2 | Spain | 02 May 2023 | |
Plaque psoriasis | Phase 2 | United Kingdom | 02 May 2023 |
Phase 2 | 229 | Placebo (Placebo) | dixvcbriob = lvaljaraqa nytqnyrbce (pnufwibzyn, eozvcgkckc - jnogceeewy) View more | - | 04 Apr 2025 | ||
(DC-806 200 mg BID) | dixvcbriob = wjgerfrrel nytqnyrbce (pnufwibzyn, newxwndskp - fdmpgbkmue) View more | ||||||
Corporate Publications Manual | Phase 1 | 32 | DC-806 200 mg | pocgakbryg(fgglcdfizy) = hbkzzhqjgw imyguevhqu (oikmgyjaoq ) View more | Positive | 11 Oct 2022 | |
DC-806 800 mg | pocgakbryg(fgglcdfizy) = vhfzkrfnwg imyguevhqu (oikmgyjaoq ) View more |